Background: While the negative prognostic role of BRAF V600E mutation in metastatic colorectal cancer (mCRC) is well established, the impact of BRAF codons 594 and 596 mutations, occurring in <1% of CRCs, is completely unknown. The present work aims to describe clinical, pathological and molecular features and prognosis of BRAF codons 594 and 596 mutant mCRCs, compared with BRAF V600E mutant and wild-type ones. Results: Ten patients bearing BRAF codons 594 or 596 mutated tumors were identified and compared with 77 and 542 patients bearing BRAF V600E mutated and BRAF wild-type tumors, respectively. While BRAF V600E mutated tumors were more frequently right-sided, mucinous and with peritoneal spread, BRAF 594 or 596 mutated were more frequently rectal, nonmucinous and with no peritoneal spread. All BRAF 594 or 596 mutated tumors were microsatellite stable. Patients with BRAF codons 594 or 596 mutated tumors had markedly longer overall survival (OS) when compared with BRAF V600E mutated [median OS: 62.0 versus 12.6 months; hazard ratio: 0.36 (95% confidence interval 0.20-0.64), P = 0.002], both at univariate and multivariate analyses.
introduction
BRAF testing allows to identify a subgroup of metastatic colorectal cancer (mCRC) patients (i.e. those harboring V600E mutation) who derive modest benefit from standard treatments and have extremely poor prognosis [1] [2] [3] . BRAF V600E mutated mCRC share peculiar clinical and pathological characteristics: they are more frequent in women than men; are often right-sided; present mucinous histology and microsatellite instability (MSI high); spread to lymph nodes and peritoneum [4] [5] [6] . When liver metastases are radically resected, BRAF V600E mutated tumors often relapse early, due to the occurrence of extrahepatic lesions [7, 8] .
In this patients' subgroup, first-line doublets plus a monoclonal antibody achieved unsatisfactory outcomes [2] and there is growing evidence on BRAF V600E mutation as a biomarker of resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies [9, 10] . First-line chemotherapy with FOLFOXIRI plus bevacizumab [11, 12] has been recently shown to provide encouraging results in this subgroup [13] .
Based on these considerations and according to the recommendations of international clinical guidelines [14, 15] , BRAF testing has entered the clinical practice worldwide.
Direct sequencing has been the preferred technique to detect BRAF mutations for long and is still widely used in many laboratories. The portion of BRAF gene that is amplified and then sequenced also includes codons 594 and 596, mapping close to codon 600 and mutated in <1% of CRCs [16] . Recently, more accurate and sensitive technologies have been developed, so that assays able to provide a comprehensive overview of genomic alterations that may drive clinical decisions are currently adopted in molecular laboratories [17] . These technologies often include also the evaluation of BRAF mutations in codons 594 and 596, beyond codon 600.
Nevertheless, the clinical impact of these mutations is completely unknown, so that oncologists frequently face the dilemma of how to interpret these findings and how to properly translate this information into clinical practice. Do these mutations share with BRAF V600E mutation the same pathogenic effect? Do BRAF 594 or 596 mutated tumors share with BRAF V600E mutated the same clinical and pathological characteristics? Do they confer the same dismal prognosis?
We collected samples and clinical data from patients bearing these rare alterations and compared their clinical and pathological characteristics as well as their clinical outcome with those of patients bearing BRAF V600E mutated and BRAF wild-type mCRCs.
patients and methods

patients and molecular analyses
We retrospectively collected clinical data from mCRC patients treated at three Italian Institutions between October 2006 and October 2014.
Tumors' blocks from primary tumors (80%) and/or paired metastases (20%) were first analyzed for KRAS and NRAS codon 12, 13, 59, 61, 117 and 146 and BRAF codon 594, 596 and 600 status by means of direct sequencing or matrix assisted laser desorption ionization time-of-flight MassArray® (Sequenom, San Diego, CA). All samples were from treatment naïve patients. Heterogeneity Score (HS) was calculated as previously described [18] . Next-generation sequencing of 50 genes' hotspot regions included in the Hotspot Cancer Panel v2 (Life Technologies) was then carried out by using the Ion Torrent Personal Genome Machine platform (Life Technologies) [19] in BRAF codon 594 or 596 mutated samples. MSI status was assessed as previously described [20] .
statistics
Fisher's exact test or χ 2 test was used when appropriate to compare clinical and biological features according to BRAF mutational status. Overall survival (OS) was defined as the time from the diagnosis of metastatic disease to death due to any cause. OS analysis was determined according to the Kaplan-Meier method and survival curves were compared using the log-rank test. Statistical significance was set at P = 0.05 for a bilateral test. The correlation of mutational status and clinical and pathological characteristics with survival was assessed in univariate analyses. Cox proportional hazard model was adopted in the multivariate analysis, including as covariates variables significantly correlated with survival in the univariate analyses.
All analyses were carried out by means of MedCalc Software (Ostend, Belgium).
results
Ten mCRC patients bearing mutations in BRAF codons 594 (N = 9) or 596 (N = 1) were identified and their characteristics and survivals were compared with those of 77 patients bearing BRAF V600E mutation and 542 patients with BRAF wild-type tumors treated in the same period. RAS mutations were found in 305 (57.3%) of 532 BRAF wild-type tumors evaluable for RAS 
clinical and pathological characteristics
As shown in Table 1 , baseline characteristics of BRAF 594 or 596 mutated tumors were different when compared with BRAF V600E mutated. In particular, while BRAF V600E mutated tumors were more frequently right-sided (64%), BRAF 594 or 596 mutated were more frequently rectal (70%, P = 0.003).
Mucinous histology was reported in the 45% of BRAF V600E mutated tumors, when compared with the 20% of BRAF 594 or 596 mutated (P = 0.180). With regard to the pattern of metastatic spread, while BRAF V600E mutated tumors presented with peritoneal metastases in 35% of cases, peritoneal involvement was never reported in BRAF 594 or 596 mutated (P = 0.028).
When compared with BRAF wild-type tumors, BRAF 594 or 596 mutated tumors occurred more frequently in females (80% versus 38%, P = 0.016), and in rectum (70% versus 29%, P = 0.020), and with metachronous presentations (60% versus 31%, P = 0.080).
MSI and next-generation sequencing analyses
Notably, all BRAF 594 or 596 mutated samples were classified as microsatellite stable. At the next-generation sequencing of 50 genes' hotspot regions, as above mentioned, we found that 2 of 10 BRAF 594 and 596 mutated samples had concomitant non-exon 2 KRAS mutations, namely a NRAS G13V and a KRAS A146T, with 10% and 20% of mutant alleles, respectively (22% and 33% when normalizing for neoplastic cells content). None of BRAF V600E mutated samples displayed other RAS mutations (P = 0.012) ( Table 2) . Notably, the HS for BRAF 594 or 596 mutations was significantly lower in samples bearing other alterations in the EGFR axis (RAS or PTEN mutations) than in samples not bearing other mutations (P = 0.034).
BRAF mutations and prognosis
When looking at OS results, at a median follow-up of 45.6 months, the poor prognosis of patients bearing BRAF V600E mutated tumors was confirmed {median OS: 12.6 versus 35.9 months in BRAF wild-type; hazard ratio (HR): 5.70 [95% confidence interval (CI) 3.74-8.69], P < 0.001} (Figure 1) . Conversely, BRAF 594 or 596 mutated patients showed a trend toward longer OS when compared with BRAF wild-type [62.0 versus 35.9 months; Table 4 . Three of four patients treated with upfront chemotherapy plus cetuximab achieved partial response.
Six (60%) of 10 patients bearing BRAF 594 or 596 mutated tumors underwent radical resections of their metastases, when compared with 9 (12%) of 77 patients BRAF V600E mutation (P = 0.001). When including the radical resection of metastases as a covariate in the multivariable model, BRAF 594 or 596 mutations retained their positive association with OS [HR: 0.27 (95% CI 0.08-0.86), P = 0.027] (supplementary Table S1 , available at Annals of Oncology online).
discussion
BRAF codons 594 and 596 mutations identify mCRCs with different clinical, pathological and prognostic features when compared with BRAF V600E mutated tumors. Notably, while the frequency of MSI high in BRAF V600E mutated tumors is relatively high even in the metastatic stage (∼20%), all BRAF codons 594 or 596 mutated samples were classified as microsatellite stable. Moreover, while the concomitant detection of RAS and BRAF V600E mutations is extremely rare (0-0.001%), since they are mutually exclusive drivers of oncogene addiction, our nextgeneration sequencing results show the concomitant presence of RAS and BRAF codons 594 or 596 mutations in 2 of 10 samples. Notably, the HS for these mutations is significantly lower in samples bearing other molecular alterations activating the EGFR pathway than in samples not bearing other alterations. This suggests that, at least in some cases, rare BRAF mutations may confer less proliferative advantage to cancer cells when compared with other mutations with a negative prognostic impact.
Overall, these results lead to conclude that the clinical and biological impact of BRAF codons 594 and 596 mutations is profoundly different than BRAF V600E. Even if some clinical differences between BRAF codons 594 or 596 mutated and wildtype tumors were described, and a trend toward longer survival was observed, further investigations are needed to confirm the peculiarity of these rare molecular alterations among non-V600E mutated tumors. Clear limitations of our analysis are the low number of BRAF 594 and 596 mutated patients, in line with the very low frequency of these alterations, and the retrospective nature of the present series.
We could not assess the efficacy of anti-EGFR monoclonal antibodies in this rare population, since none of BRAF 594 or 596 mutated patients received an anti-EGFR as monotherapy. However, De Roock et al. reported in the wide series of the European Consortium (N = 773) that a patient bearing BRAF D594G mutated mCRC achieved response to cetuximab monotherapy [21] . Based on these findings, BRAF 594 or 596 mutated patients should not be excluded from receiving anti-EGFR monoclonal antibodies.
At the same time, the absence of a negative prognostic impact may have important implications in the daily management of these patients, also with regard to the choice of the intensity of the first-line chemotherapy regimen.
Is there a biological rationale supporting present findings? It is well known that BRAF V600E protein is 500-fold activated and stimulates constitutive MEK-ERK signaling in cells. Preclinical data show that BRAF 594 and 596 mutations are not responsible for the hyperactivation of the downstream kinase pathways [22] . In fact, even if codons 594 and 596 are located in the kinase activation segment of BRAF, they are DFG motif inactivating mutations, associated with impaired transforming ability [23] . Conformational changes induced by BRAF 594 and 596 mutations increase the heterodimerization of BRAF with wild-type CRAF [24] , thus inducing an indirect and modest activation of MAPK pathway [25] . This is in line with preclinical data on a BRAF G596R mutated cell line (NCIH508) showing sensitiveness to anti-EGFR treatment [26] .
In conclusion, BRAF 594 or 596 mutations identify a rare and previously unexplored molecular subtype of mCRC with clinical and pathological features different from BRAF V600E mutated. This novel knowledge provides an intriguing background to investigate new target approaches in this patients' population and represents a progress toward more personalized cancer medicine. 
